Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial

RATIONALE: Inhaled tobramycin and oral azithromycin are common chronic therapies in people with cystic fibrosis and Pseudomonas aeruginosa airway infection. Some studies have shown that azithromycin can reduce the ability of tobramycin to kill P. aeruginosa. This trial was done to test the effects o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, David P, Singh, Pradeep K, Baines, Arthur, Caverly, Lindsay J, Chmiel, James F, GIbson, Ronald L, Lascano, Jorge, Morgan, Sarah J, Retsch-Bogart, George, Saiman, Lisa, Sadeghi, Hossein, Billings, Joanne L, Heltshe, Sonya L, Kirby, Shannon, Kong, Ada, Nick, Jerry A, Mayer-Hamblett, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Cystic Fibrosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043040/
https://www.ncbi.nlm.nih.gov/pubmed/34706982
http://dx.doi.org/10.1136/thoraxjnl-2021-217782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043040/
https://www.ncbi.nlm.nih.gov/pubmed/34706982
http://dx.doi.org/10.1136/thoraxjnl-2021-217782

Ejemplares similares